Customised Services in Preclinical Inflammation

Publicerad 2022-01-18

Redoxis signs license agreement with VivoLogica

Redoxis AB recently signed a license agreement with VivoLogica for use of their software platform for in vivo study management. This is an important step in our journey and aim to provide highest quality data in all our preclinical projects. We are looking forward to our continued collaboration with the VivoLogica team.

"VivoLogica helps us to save time, focus on the right tasks and secures data quality during the whole process. We gladly recommend the use of VivoLogica during in vivo studies." - Malin Hultqvist Hopkins, CEO Redoxis AB.

Read more about Vivologica here Rat